Drug utilization in very premature infants in neonatal intensive care units

Dev Pharmacol Ther. 1991;17(3-4):167-71. doi: 10.1159/000457518.

Abstract

Neonatal drug utilization in very premature infants (gestational age (GA) 24-29 weeks), requiring intubation and mechanical ventilation at birth was registered as part of a multicenter controlled clinical trial of high-dose versus low-dose bovine surfactant (initial doses 100 mg/kg birth weight (b.w.) versus 50 mg/kg b.w.). Drug utilization during 4 weeks after birth was analyzed in 164 infants (mean GA 27.2 +/- 1.2 (SD) weeks, b.w. 970 +/- 145 g (SD)). More than half of the study infants received antibiotics (98.8%), sedatives and analgesics (91.5%), sodium bicarbonate (78%), solutions for volume replacement (62.8%), methylxanthines (56.7%) and catecholamines (52.4%). It may be concluded that the pattern of drug usage indicates a high incidence of proven or suspected infections and circulatory and respiratory disorders reflecting the high-risk state of study infants.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Dose-Response Relationship, Drug
  • Drug Utilization*
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intensive Care Units, Neonatal*
  • Surface-Active Agents / therapeutic use

Substances

  • Surface-Active Agents